Kihara James 4
4 · ACADIA PHARMACEUTICALS INC · Filed May 2, 2025
Insider Transaction Report
Form 4
Kihara James
PRINCIPAL ACCOUNTING OFFICER
Transactions
- Sale
Common Stock
2025-05-02$14.60/sh−1,327$19,374→ 23,526 total - Exercise/Conversion
Common Stock
2025-05-01+2,596→ 24,853 total - Exercise/Conversion
Restricted Stock Units
2025-05-01−2,596→ 5,192 total→ Common Stock (2,596 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]The restricted stock units vest in four equal annual installments beginning May 1, 2024.